AbbVie Ordered to Pay $150 Million Damages in ‘Low-T’ Trial
- $150 million verdict is first over Low-T testosterone booster
- Oregon man blamed 2012 cardiac arrest on company’s AndroGel
Abbott Laboratories' AndroGel
Photographer: Daniel Acker/BloombergThis article is for subscribers only.
AbbVie Inc. was ordered to pay $150 million to an Oregon man who accused the drugmaker of hiding the heart-attack risks of its AndroGel testosterone booster, but the company’s first trial loss probably won’t stand because jurors awarded no compensation for injuries.
AbbVie misled Jesse Mitchell and his doctor about AndroGel’s propensity for causing blood clots, which can lead to fatal heart attacks, a federal court jury in Chicago concluded Monday. Mitchell, a 54-year-old laundry manager, suffered a heart attack in 2012 after taking AndroGel for four years.